Catalyst Wire Dossier Catalyst Wire Dossier

13-valent pneumococcal polysaccharide conjugate vaccine

PCV13 · Sinovac Life Sciences Co., Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for 13-valent pneumococcal polysaccharide conjugate vaccine, covering 2020-10-14 to 2026-01-28. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine [Phase 1]

See pricing